| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bellerophon Therapeutics Inc. | INOpulse delivery device | Pulmonary Arterial Hypertension (PAH) | Phase 3 | Inhalation | Cardiology | |
| Bellerophon Therapeutics Inc. | INOpulse Inhaled Nitric Oxide | COVID-19 | Phase 3 | Inhalation | COVID-19 | |
| Bellerophon Therapeutics Inc. | INOpulse delivery device - (REBUILD) | Pulmonary hypertension associated with Fibrotic Interstitial Lung Disease | Phase 3 | Trial Discontinued | Inhalation | Respiratory |
| Bellerophon Therapeutics Inc. | INOpulse Inhaled Nitric Oxide | COVID-19 | Phase 3 | Inhalation | COVID-19 | |
| Bellerophon Therapeutics Inc. | INOpulse Inhaled Nitric Oxide | COVID-19 | Phase 3 | Inhalation | COVID-19 | |
| Bellicum Pharmaceuticals Inc. | Rivo-cel - (THRIVE) | Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) | Phase 2/3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Ociperlimab (BGB-A1217) and tislelizumab - (AdvanTig-301) | Non Small Cell Lung Cancer | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | BRUKINSA (zanubrutinib) | B-cell malignancies intolerant to ibrutinib and/or acalabrutinib | Phase 2 | Oral | Oncology |